Dubai, United Arab Emirates - Monday, September 30th 2013 [ME NewsWire]
The Government of Dubai has signalled an ambition to increase the amount of medicines manufactured locally, which presents an opportunity for Indian investors and pharmaceutical manufacturers. The GCC countries have the highest levels of imported medicines in the world; as an example, the UAE alone imports 80% of the drugs consumed by its population from international markets. Importing such high levels of medication leaves the UAE vulnerable to price increases as a result of currency fluctuations and supply regularity issues. DuBiotech is keen to realise the opportunity presented by the need for local pharmaceutical manufacturing by facilitating the establishment of global biotechnology and pharmaceutical companies, such as those based in India to establish their regional hub in the freezone.
Marwan Abdulaziz, Executive Director of DuBiotech said: “Strengthening our partnership with India is an integral part of DuBiotech’s strategy to build and stimulate the UAE’s lifescience industry. By supporting Indian firms in their move to the Middle East and providing a sound platform in Dubai from which they can operate, we are exponentially building on the potential for R&D collaboration; knowledge and technology exchange and ultimately addressing the imbalance in levels of imported drugs versus locally manufactured pharma products.
“The GCC’s lifescience industry is evolving from a simple outsourcing destination to a hub of true biopharmaceutical activity. I am proud to say that DuBiotech is a key part of this. Our business park is already home to a number of well-reputed Indian companies. I hope that by strengthening our relationship with the Indian Consul General we can build on the opportunity to develop new products and enhance innovation for the benefit of the UAE community.”
Major Indian companies already based at DuBiotech include a blend of biotechnology and pharmaceutical companies such as Sun Pharma, Epygen, Wockhardt, Lupin, and Life Cell and NeoBiocon, a joint venture company between UAE-based Neopharma and the Indian biotech innovator Biocon.
Sanjay Verma, the Consul General of India in Dubai also commented: “Economic and cultural links between the UAE with India date back more than a century and today trade between our two countries is worth in excess of US$ 44 billion. I have seen a wealth of interest from Indian lifescience companies and potential investors in coming to Dubai to explore the possibilities. I look forward to assisting in their endeavours where I can.”
In 2012, DuBiotech witnessed exceptional growth, issuing 40 commercial licences in comparison to 21 in 2011. This reflects a year-on-year increase of 50 per cent, now taking the total number of companies based in the free zone to 126. The business centre is also now 100 per cent occupied with a mix of both multinational and small and medium sized firms. DuBiotech offers organisations based in the freezone, services in regulatory affairs management, partnership development, registration and licensing, leasing and government services to help both start-ups and international firms set up and achieve their respective commercial targets.
ENDS
About DuBiotech
Dubai Biotechnology and Research Park (DuBiotech), a member of TECOM Investments, is a free zone business park dedicated to fostering the growth of the life sciences industry in the region. DuBiotech was established to support the Government of Dubai’s vision to transform the UAE into a knowledge-based economy and develop the region’s talent pool.
DuBiotech offers world-class infrastructure and cutting edge research and development facilities, specifically designed and built for the field of biotechnology, pharmaceutical, medical and scientific device, food and agricultural industries. The free zone can support both start-ups and international firms looking for a regional base for their Middle East or global operations. The park is central to a community that is committed to the industry’s success by bringing together business, regulators and Government in partnership.
Since its launch in 2005, DuBiotech has rapidly grown into a community of 126 life sciences companies such as Pfizer, Genzyme, Merck-Serono, Amgen, Bristol-Myers Squibb, Maquet, National Reference Lab, Firmenich and IFF.
For further information on DuBiotech, please visit our website: www.dubiotech.ae.
Contacts
Nicola Hooper, Bell Pottinger
+971 558862254
Layla Haroon, Bell Pottinger
+971 55 636 0425
Permalink: http://me-newswire.net/news/8664/en
No comments:
Post a Comment